JinYi Interconnect Limited, a strategic extension of the leading international venture capital firm Index Ventures in the Asian market, was established in Hong Kong in 2025, with the mission of "connecting global capital and driving biomedical innovation in Asia." The company focuses on promoting innovation in the Asian biopharmaceutical and technology sectors, and is committed to building an open, collaborative, and efficient industrial ecosystem to help biopharmaceutical companies in China and Asia achieve the leap from technological breakthroughs to global commercialization.

I. Mission and original aspiration

Driving Asian Biomedical Innovation Through Capital JinYi firmly believes that biopharmaceuticals are a key area concerning human health and the future. Driven by a dual engine of "capital + innovation," and leveraging its parent company's global financial strength, investment experience, and network resources, the company focuses on cutting-edge areas such as gene therapy, precision medicine, digital health, and AI-driven drug development, aiming to become a leader in Asian biomedical investment and innovation. The company's vision is to propel the Asian biopharmaceutical industry to a more important position in the global value chain through continuous value investment and ecosystem building, contributing Chinese wisdom and Asian strength to human health.

 II. Core Values: Innovation-Driven, Win-Win Cooperation, Long-Term Vision 

JinYi Interconnect adheres to the "innovation-driven" philosophy, focusing not only on the cutting-edge and disruptive nature of technologies but also on the practical application and transformation of innovative achievements. Based on "win-win cooperation," the company actively establishes deep partnerships with local research institutions, hospitals, governments, and industry partners, building a comprehensive support system from laboratory to market. Simultaneously, the company adheres to a "long-term vision" investment philosophy, not pursuing short-term gains but rather accompanying enterprises to grow and achieve sustainable development through continuous capital injection, strategic guidance, and resource integration.

III. Strategic Layout: Deepening Roots in Asia, Focusing on Cutting-Edge Technologies, Empowering the Entire Chain

Strategically, JinYi Interconnect focuses on Asia as its core battleground, prioritizing high-growth potential markets such as Mainland China, Hong Kong, Singapore, and India. The company focuses on niche sectors such as cancer treatment, AI drug discovery, gut microbiota, gene editing, and cell and gene therapy, covering the entire lifecycle from early-stage R&D to mature commercialization through a multi-stage investment strategy.  Furthermore, the company provides comprehensive support to enterprises through various means, including establishing a post-investment management team, hosting industry summits, and building a data-driven evaluation system. This support encompasses strategic planning, technology integration, and market expansion, facilitating the rapid implementation of innovative achievements.

IV. Future Outlook: Technology Empowerment, International Leadership, and Ecosystem Co-construction

Looking to the future, JinYi Interconnect will continue to increase its investment in emerging technologies such as artificial intelligence, big data, and blockchain, using technology to empower industrial upgrading and drive the development of biopharmaceuticals towards digitalization and intelligence. In terms of internationalization, the company will leverage Hong Kong's role as a bridge between international financial centers to help Chinese biopharmaceutical companies go global and participate in international competition and cooperation. Ultimately, JinYi Interconnect is committed to building an open, collaborative, and inclusive biopharmaceutical innovation ecosystem, working with partners to promote the prosperity and progress of the Asian biopharmaceutical industry.

JinYi Interconnect is not only a connector of capital but also a catalyst for innovation and a co-builder of the industry. Against the backdrop of continuously released policy dividends and deepening technological revolution, the company will continue to cultivate the biopharmaceutical field with unwavering faith, a professional team, and a global vision, striving tirelessly to achieve the grand goal of "Healthy Asia, Innovative Future."